KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Finished Goods (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Finished Goods for 13 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 28.44% to $21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.1 million through Dec 2025, up 28.44% year-over-year, with the annual reading at $21.1 million for FY2025, 28.44% up from the prior year.
  • Finished Goods for Q4 2025 was $21.1 million at Supernus Pharmaceuticals, up from $16.7 million in the prior quarter.
  • The five-year high for Finished Goods was $46.7 million in Q3 2022, with the low at $12.5 million in Q3 2021.
  • Average Finished Goods over 5 years is $27.6 million, with a median of $29.3 million recorded in 2023.
  • The sharpest move saw Finished Goods soared 272.49% in 2022, then plummeted 45.05% in 2024.
  • Over 5 years, Finished Goods stood at $32.9 million in 2021, then rose by 6.34% to $35.0 million in 2022, then dropped by 14.54% to $29.9 million in 2023, then tumbled by 45.05% to $16.4 million in 2024, then grew by 28.44% to $21.1 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $21.1 million, $16.7 million, and $20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.